Background: Myeloid cell leukemia-1 (Mcl-1) is a member of the Bcl-2 family, which inhibits cell apoptosis by sequestering pro-apoptotic proteins Bim and Bid. Mcl-1 overexpression has been associated with progression in leukemia and some solid tumors including prostate cancer (PCa). However, the regulatory mechanism for Mcl-1 expression in PCa cells remains elusive. Results: Immunohistochemical analyses revealed that Mcl-1 expression was elevated in PCa specimens with high Gleason grades and further significantly increased in bone metastasis, suggesting a pivotal role of Mcl-1 in PCa metastasis. We further found that vascular endothelial growth factor (VEGF) is a novel regulator of Mcl-1 expression in PCa cells. Inhibition of endogenous Mcl-1 induced apoptosis, indicating that Mcl-1 is an important survival factor in PCa cells. Neuropilin-1 (NRP1), the "co-receptor" for VEGF 165 isoform, was found to be highly expressed in PCa cells, and indispensible in the regulation of Mcl-1. Intriguingly, VEGF 165 promoted physical interaction between NRP1 and hepatocyte growth factor (HGF) receptor c-MET, and facilitated c-MET phosphorylation via a NRP1-dependent mechanism. VEGF 165 induction of Mcl-1 may involve rapid activation of Src kinases and signal transducers and activators of transcription 3 (Stat3). Importantly, NRP1 overexpression and c-MET activation were positively associated with progression and bone metastasis in human PCa specimens and xenograft tissues.
Background
Acquisition of apoptosis resistance is characteristic of invasive tumor cells. Elevated expression of anti-apoptotic proteins is associated with tumor progression clinically and experimentally [1] . Myeloid cell leukemia-1 (Mcl-1), a member of the Bcl-2 family, sequesters proapoptotic proteins Bim and Bid, thereby inhibiting mitochondrial outer membrane permeabilization, a central control point of apoptosis [2, 3] . Mcl-1 overexpression is associated with progression in leukemia [4] and some solid tumors including prostate cancer (PCa) [5] [6] [7] . Mcl-1 was elevated in primary PCa with high Gleason grades and metastatic tumors compared to that in prostatic intraepithelial neoplasia (PIN) or lower grade tumors, suggesting a pivotal role of Mcl-1 in PCa progression [5] .
Angiogenesis favors tumor cell survival, thereby contributing to progression [1] . Vascular endothelial growth factor (VEGF) is a critical pro-angiogenic factor that induces proliferation and migration of endothelial cells within tumor vasculature [8] . VEGF is expressed as several alternately spliced isoforms. VEGF 165 is pre dominant, with optimal bioavailability, and responsible for VEGF biological potency, whereas VEGF 121 is less potent but freely diffusible. VEGF binds two highly-related receptor tyrosine kinases, VEGF-R1 and VEGF-R2 [8] . Neuropilin-1 (NRP1) was originally identified as a receptor for the semaphorin 3 subfamily mediating neuronal guidance and axonal growth [9] . It was subsequently found to specifically bind VEGF 165 but not VEGF 121 on endothelial cells and tumor cells [9, 10] . NRP1 lacks a typical kinase domain, primarily functioning as a "co-receptor" to form ligand-specific receptor complexes. In response to VEGF 165 , NRP1 couples with VEGF-Rs to signal in endothelial cells. Though VEGF-R1 and VEGF-R2 are usually absent or expressed at very low levels in PCa cells [11] , aberrant upregulation of NRP1 has been frequently observed in high grade and metastatic PCa and other solid tumors [9, [12] [13] [14] [15] [16] . Ectopic expression of NRP1 in PCa cells induced cell migration, increased tumor size and microvessel density, and inhibited apoptosis [17] . These observations suggested that NRP1 may be critical for PCa progression. Nonetheless, the mechanism by which NRP1 transmits VEGF signaling in PCa cells lacking VEGF-Rs remains unclear.
Previously we reported that serum VEGF levels correlate to bone metastatic status in PCa patients, and activation of VEGF signaling in PCa cells is associated with invasive phenotypes in experimental models [18] . In this study, we correlate Mcl-1 overexpression to PCa progression towards bone metastasis, and provide evidence that VEGF regulates Mcl-1 expression through NRP1-dependent activation of c-MET in PCa cells.
Results

Elevated Mcl-1 expression is associated with PCa progress and bone metastasis
To investigate the clinical significance of Mcl-1 in PCa progression, immunohistochemical (IHC) analyses were performed to determine the expression of Mcl-1 in a human PCa tissue microarray with matched normal adjacent tissue and bone metastatic bone specimens ( Figure 1a) . We defined tumors with Gleason score 2-6 as well-differentiated (n = 2), Gleason score 7 as intermediately-differentiated (n = 26) and Gleason score 8-10 as poorly-differentiated (n = 43). Mcl-1 immunointensity was increased from normal tissues to well-differentiated cancer and further elevated in high grade PCa, although the difference between Mcl-1 intensity in intermediateand poorly-differentiated cancers was not statistically significant (p = 0.93). Intriguingly, Mcl-1 staining in bone metastatic tumors (n = 6) was remarkably increased compared to that in either intermediate-or poorly-differentiated PCa (p < 0.002). These data correlated elevated Mcl-1 expression to clinical PCa progression, particularly bone metastasis.
Mcl-1 is a survival factor in human PCa cells
We have established several lines of human PCa models that closely mimic the clinical progression of PCa bone metastasis, including the ARCaP model [19, 20] . When inoculated either orthotopically or intracardially, ARCaP M cells are capable of metastasizing spontaneously to bone and soft tissues, forming mixed osteoblastic and osteolytic lesions in mouse skeleton [19, 21, 22] . The ARCaP M -C2 subclone, derived from metastatic bone tissues after two rounds of intracardiac injection of ARCaP M cells in athymic mice, forms predictable metastases to bone, adrenal gland and other soft tissue with higher propensity and shorter latency [21, 22] (Figure 1b 
VEGF regulates Mcl-1 expression in human PCa cells
Previously we reported that ARCaP M cells express high levels of endogenous VEGF, regulated by a cyclic AMPresponse element binding protein (CREB)-hypoxia-inducible factor (HIF)-dependent mechanism in normoxic conditions [18] . In the present study, RT-PCR assay that could differentiate mRNA expression of VEGF 165 and VEGF 121 isoforms [18] was performed in ARCaP M and ARCaP M -C2 cells, showing a significant increase in the expression of both VEGF isoforms in ARCaP M -C2 cells, as confirmed at protein level by enzyme-linked immunosorbent assay (ELISA) (Figure 2a) . Similarly, C4-2 cells express higher levels of VEGF when compared to LNCaP cells (Additional file 1, Figure S1b ). These data suggested that VEGF expression is elevated in metastatic PCa cells.
VEGF potently stimulates endothelial cell proliferation and migration, an underlying mechanism for angiogenesis during tumor progression. However, neither exogenous human VEGF 165 (Figure 2b 
Differential expression of VEGF-Rs in PCa cells
Expression of VEGF-Rs was examined in several PCa cell lines with human umbilical vein endothelial cells (HUVEC) as a positive control (Figure 3a , and Additional file 1, Figure S1f ). VEGF-R1 was undetectable in PCa cells. Only very low expression of VEGF-R2 could be observed in ARCaP M -C2 cells. However, NRP1 was ubiquitously expressed in PCa cells at a level comparable to that in HUVEC, and higher in metastatic ARCaP M -C2, PC3, C4-2 and C4-2B cells. NRP2, the "co-receptor" for VEGF-C [8] , was not detected in PCa cells. These data implied that NRP1 may be the major receptor mediating VEGF effects in PCa cells. 
c-MET signaling is required for VEGF regulation of Mcl-1 in PCa cells
Since NRP1 does not contain typical kinase receptor sequences [24] , we hypothesized that NRP1 may interact with certain tyrosine kinase receptor(s) to transmit VEGF autocrine signal in PCa cells lacking VEGF-Rs. Two recent studies independently demonstrated that NRP1 physically binds c-MET, and potentiates c-MET activation in response to HGF stimulation in human glioma and pancreatic cancer cells [25, 26] . It is therefore plausible that c-MET may be involved in VEGF regulation of Mcl-1 in PCa cells. Indeed, HGF activation of c-MET signaling has been shown to transcriptionally increase Mcl-1 expression in primary human hepatocytes [27] . Figure 4c ). PHA-665752, a c-MET selective inhibitor [28] , was used to treat ARCaP M cells prior to addition of VEGF 165 . PHA-665752 significantly attenuated VEGF 165 induction of Mcl-1 in ARCaP M cells (Figure 4d) . These data indicated that c-MET signaling is required for VEGF regulation of Mcl-1 in PCa cells.
VEGF induces c-MET activation by a NRP1-dependent mechanism in PCa cells
c-MET activation involves phosphorylation of several tyrosine residues including those at positions 1230, 1234, and 1235 [29] . To assess whether VEGF 165 could induce c-MET activation, and whether this process was mediated by NRP1, ARCaP M cells were transiently transfected with NRP1 siRNA or control siRNA before VEGF 165 treatment. VEGF 165 induced rapid phosphorylation of c-MET at Tyr1230/1234/1235 residues in ARCaP M cells transfected with control siRNA, but this effect was significantly attenuated by expression of NRP1 siRNA. Expression of total c-MET protein was not affected by siRNA treatment (Figure 5a ). These data indicated that VEGF 165 activated c-MET signaling independent of HGF, and NRP1 may be indispensible in this process.
VEGF promotes interaction between NRP1 and c-MET in PCa cells
To explore whether VEGF could induce physical interaction between NRP1 and c-MET, an immunoprecipitation assay was performed in ARCaP M cells treated with VEGF 165 for varying times. First, endogenous NRP1 protein was immunoprecipitated (Figure 5b, upper) . There was a constitutive association between c-MET and NRP1 in the absence of VEGF 165 . Upon VEGF 165 treatment, presence of c-MET in the NRP1 immunoprecipitates increased at 30 min and returned to baseline at 60 min. Phosphorylated c-MET (p-c-MET) significantly increased at 15 min following VEGF 165 treatment, reached a peak at 30 min and slightly decreased in 60 min. Reciprocal immunoprecipitation with anti-c-MET antibody confirmed an association of NRP1 with c-MET in the absence of VEGF 165 . The presence of NRP1 and p-c-MET in the protein complex exhibited a similar time course following VEGF 165 stimulation, with the peak at 30 min (Figure 5b, low) .
Confocal microscopy was performed to determine whether VEGF 165 promotes NRP1 interaction with c-MET 
NRP1 overexpression and c-MET activation are positively associated with human PCa progression and bone metastasis
To validate the clinical significance of NRP1-c-MET signaling in PCa progression, and avoid the potential bias from using human PCa cell lines, IHC analyses were performed to determine the expression of NRP1 and p-c-MET in human PCa tissue specimens. Prostatic tissue specimens of normal/benign glands, primary and bone metastatic tumors were analyzed. NRP1 expression was increased from normal/benign glands (0/5) or well-differentiated cancer (1/5) to poorly-differentiated cancers (5/5) and bone metastatic tissues (5/5) (Figure 8a ). NRP1 staining was also determined in tumor specimens from the ARCaP M xenograft model in which ARCaP M cells were inoculated into athymic mice orthotopically, resulting in skeletal metastases with a short latency [21] . Consistently, NRP1 expression was significantly greater in bone metastatic tumors than in primary tumors (Figure 8b ).
We and others have reported that c-MET overexpression is positively associated with PCa progression [34, 35] . As shown in Figure 8c , p-c-MET was expressed at a low level in normal human prostatic tissue, but increased significantly from well-differentiated and intermediate to poorly-differentiated primary PCa. Importantly, bone metastatic PCa specimens displayed a higher expression of p-c-MET than primary PCa. p-c-MET expression was also remarkably increased in bone metastatic ARCaP M tumors (Figure 8d ).
Discussion
Aberrant overexpression of Mcl-1 has been associated with poor prognosis and resistance to chemotherapy in a variety of human cancers [36] . Sensitizing tumor cells to apoptosis induction by selectively targeting Mcl-1, in combination with conventional chemotherapy, has emerged as an attractive therapeutic strategy [3, 37] . In this study, we presented evidence that elevated Mcl-1 expression is associated with clinical PCa progression, particularly bone metastasis. We further showed that activation of VEGF-NRP1-c-MET signaling is responsible for Mcl-1 expression, which may confer survival advantages allowing PCa cells to evade apoptosis and progress towards invasive states ( Figure 6 ).
Only limited information are available on Mcl-1 expression profile in PCa. An early study found that Mcl-1 expression was increased at tumors (81%) compared with only 38% in PIN. The percentage of Mcl-1-positive cells was typically higher in Gleason grade 8-10 tumors and metastasis than lower grade tumors, but there was no significant difference in Mcl-1 immunointensity between high grade tumors (47%) and metastasis in lymph node (38%) and bone (50) [5] . Our present study confirmed elevated Mcl-1 expression in high grade (≥ 7) PCa, though the difference between Gleason score 7 and 8-10 tumors is not statistically significant. Intriguingly, our results revealed a remarkable increase in Mcl-1 immunointensity in bone metastasis compared to primary tumors, indicating that Mcl-1 overexpression is positively correlated to PCa progression towards metastatic status in clinical situation.
Accumulating evidence suggests that the function of VEGF in tumor progression may not be limited to angiogenesis [38] . Numerous tumor cells express significant levels of VEGF-Rs, which could engage VEGF and initiate multiple signaling responses involved in cell proliferation, survival and migration. VEGF autocrine signaling confers a degree of self-sufficiency that may be crucial to metastasis as the microenvironment becomes increasingly hostile. Nonetheless, it remains controversial whether VEGF has significant autocrine effects in PCa cells, since the "classical" VEGF-Rs, i.e., VEGF-R1 and -R2, are undetectable in most established PCa cell lines [11, 39, 40] . Previously we reported that serum VEGF is positively associated with bone metastatic status in PCa patients, and recapitulated this close association in the ARCaP model [18] . In this study, we investigated whether VEGF could affect PCa cell behavior in an autocrine manner. Intriguingly, VEGF 165 was found to be capable of inducing Mcl-1 expression within a non-saturating range, suggesting it may act as a survival factor in PCa cells. Moreover, NRP1 was found to be highly expressed by PCa cell lines and displayed a positive association with invasiveness, suggesting that it may be the primary receptor responsible for VEGF autocrine NRP1 is not a typical "signaling receptor" since it lacks sequences predicted to have kinase receptor activities [24] . Direct interaction between NRP1 and VEGF-Rs or plexin A is essential to its function in prioritizing differential signals from VEGF 165 or semaphorin 3 in endothelial cells and nerve cells [24] . Recent studies found that 
the NRP1 intracellular domain, especially the C-terminal three amino acids (SEA-COOH), may be required for the interaction between NRP1 and its binding partners, including NRP1-interacting protein (NIP; or RGS-GAIPinteracting protein, GIPC) and VEGF-R2 [41, 42] . However, the molecular effects and mechanism for NRP1-mediated signaling in tumor cells, especially in the absence of VEGF-Rs, remain elusive. It has been proposed that NRP1 may store or sequester VEGF 165 and attract endothelial cells towards tumor, contributing to angiogenesis via juxtacrine or paracrine mechanisms [9, 17] . In this study, we investigated whether NRP1 is required for VEGF 165 autocrine signaling in PCa cells lacking VEGF-Rs. We presented evidence that NRP1 and c-MET are physically associated on plasma membrane, and in response to VEGF 165 stimulation, their interaction may significantly facilitate further recruitment and activation of c-MET. Though the structural and molecular basis for interaction between the two receptors needs to be further investigated, this study indicates for the first time that c-MET activity can be modulated by VEGF, and the NRP1-c-MET interaction may be a critical component in transmitting the VEGF survival signal in PCa cells. It may be plausible to assign c-MET phosphorylation as an indicator for activation of NRP1 autocrine signaling in tumor cells. Using human PCa tissue specimens as the "gold standard", we observed that NRP1 and p-c-MET were both significantly increased with progression of primary PCa, and further elevated in bone metastatic PCa, suggesting that activation of NRP1-c-MET signaling may be positively associated with clinical PCa progression. It is worth noting that these results need cautious interpretation since a limited number of patient specimens was examined, and the polyclonal antibody against p-c-MET has not been fully validated for immunohistochemical analysis in tissue sections.
In human primary hepatocytes, HGF transcriptionally induced Mcl-1 expression, but not Bcl-2 or Bcl-x(L) [27] . Our studies found that, however, HGF treatment did not significantly affect Mcl-1 protein expression in ARCaP M cells, suggesting HGF activation of c-MET signaling may not be sufficient to increase Mcl-1 expression. We postulated that VEGF 165 may utilize a different mechanism to regulate Mcl-1 expression in PCa cells. An important observation supporting this hypothesis is that VEGF 165 only rapidly induced Stat3 phosphorylation at Tyr705, but not altering Ser727 phosphorylation in ARCaP M cells. In hepatocytes, however, HGF triggered Ser727, but not Tyr705, phosphorylation of Stat3 [27] . It will be intriguing to investigate the role of NRP1-c-MET interaction in differentiating extracellular ligands, i.e., VEGF 165 or HGF, and activating distinct downstream cascades leading to Mcl-1 expression in a highly cell context-dependent fashion.
Mcl-1 is a protein with very short half-life and is highly regulated at multiple levels in response to survival and differentiation signals. Rapid turnover of Mcl-1 protein can be initiated by stress (such as serum withdrawal) through caspase-mediated and proteasomedependent degradation in tumor cells [3] . Previous study found that VEGF protects multiple myeloma cells against apoptosis by up-regulating Mcl-1 protein in a time-dependent manner, peaking at 6 h and returning to baseline after 24 h; change in Mcl-1 mRNA expression was not reported [43] . In ARCaP M cells, however, VEGF 165 treatment rapidly induced Mcl-1 mRNA expression and significantly increased Mcl-1 protein level at 72 h. Though whether VEGF 165 may also regulate Mcl-1 expression at other levels needs to be further investigated, the data presented here suggest that transcriptional activation, presumably mediated by Stat3, is an important mechanism for VEGF 165 induction of Mcl-1 in PCa cells.
Interrupting NRP1 functions with mimetic peptides and monoclonal antibodies is being developed in xenograft models of human cancers [44, 45] . NRP1 monoclonal antibody has been shown to effectively inhibit tumor vascular remodeling, rendering vessels more susceptible to anti-VEGF therapy [45] . If the VEGF 165 -NRP1-c-MET pathway is required for Mcl-1 expression and survival in PCa cells, it would be intriguing to evaluate whether targeting NRP1 could interrupt both NRP1-c-MET signaling in tumor cells (survival) and NRP1-VEGF-Rs signaling in endothelial cells (angiogenesis). Inhibition of NRP1 signaling may be a promising strategy alone or in combination with other therapeutic approaches for treating PCa.
Methods
Cell culture
Human PCa cell lines ARCaP M , ARCaP M -C2, PC3, LNCaP, C4-2 and C4-2B, were routinely maintained in T-medium (Invitrogen, Carlsbad, CA) with 5% fetal bovine serum (FBS). ARCaP M -C2 subclone was derived from ARCaP M bone metastatic tissues as described previously [21, 22] . Where specified, ARCaP M cells were serum-starved overnight, and treated with recombinant human VEGF 165 , VEGF 121 , HGF (R&D Systems, Minneapolis, MN), c-MET inhibitor PHA-665752 (Calbiochem, San Diego, CA), or Src kinase inhibitor (PP2) (Calbiochem) in serum-free T-medium. HUVEC (The American Type Culture Collection, Manassas, VA) were maintained in endothelial basal growth medium (EBM-2) with 2% FBS. Cell proliferation was measured using the CellTiter 96 AQ proliferation assay according to the manufacturer's instructions (Promega, Madison, WI). Viable cells were counted in triplicate using a hemacytometer and trypan blue staining.
Immunohistochemical analysis
IHC staining of NRP1 and p-c-MET on human normal/ benign prostatic glands, well-and poorly-differentiated primary PCa and bone metastatic PCa tissue specimens was performed as described previously [18] using goat anti-NRP1 antibody (C-19, Santa Cruz Biotechnology, Santa Cruz, CA; 1:100) and rabbit anti-p-c-MET (Tyr1230/1234/1235) antibody (44888G, Invitrogen; 1:100). IHC analysis of Mcl-1 expression was performed on a human PCa progression tissue microarray specimen (US BioMax, Inc., Rockville, MD) using rabbit antiMcl-1 antibody (S-19, Santa Cruz Biotechnology, 1:150). Matching normal serum was used as negative control. All IHC common reagents were obtained from Dako (Carpinteria, CA). Positive expression of NRP1, p-c-MET and Mcl-1 was defined as >15% positive staining in cell population.
Transfection
The vector harboring NRP1 cDNA (pCMV-NRP1) and the control (pCMV-XL4) (Origene, Rockville, MD) were transfected into ARCaP M cells for 48-72 h using lipofectamine 2000 (Invitrogen). Small interfering RNA (siRNA) nucleotides were transfected into ARCaP M cells according to the manufacturer's instructions. VEGF siRNA, Mcl-1 siRNA, Stat3 siRNA and control siRNA-A were purchased from Santa Cruz Biotechnology. NRP1 silencer® select validated siRNA and silencer® select control siRNA # 1 were obtained from Ambion, Inc., (Austin, TX). c-MET ON-TARGET plus siRNA and ON-TAR-GET plus siRNA control were purchased from Dharmacon, Inc, (Chicago, IL).
Western blot analysis
Total cell lysates were prepared using radioimmunoprecipitation (RIPA) buffer (Santa Cruz Biotechnology). Nuclear proteins were extracted using a Novagen kit (EMD Biosciences, San Diego, CA). Immunoblotting analysis followed standard procedure [18] 
RT-PCR
Total RNA was prepared with Qiagen RNeasy Kit (Valencia, CA), and RT-PCR was performed using the SuperScriptIII® One-Step RT-PCR kit (Invitrogen) following the manufacturer's protocol. The specific primer pairs are: 5'-GAGGAGGAGGAGGACGAGTT-3' (forward) and 5'-GTCCCGTTTTGTCCTTACGA-3' (reverse) (for Mcl-1); 5'-AGGACAGAGACTGCAAG TATGAC-3' (forward) and 5'-AACATTCAGGACCT CTCTTGA-3' (reverse) (for NRP1). The primers for VEGF, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [18] and Stat3 [46] were described previously. The primer pairs for human VEGF-R1, VEGF-R2 and NRP2 were purchased from R&D Systems.
ELISA
Subconfluent PCa cells were cultured in serum-free Tmedium for 72 h before conditioned medium was collected. VEGF concentrations were analyzed using a Quantikine ELISA kit (R&D Systems) and normalized with total protein concentrations in CM.
Immunofluorescence and confocal imaging
Immunofluorescence was performed as described previously [47] . Goat anti-NRP1 antibody (C-19), rabbit anti-c-MET antibody (C-12, Santa Cruz Biotechnology), or rabbit anti-p-c-MET (Tyr1230/1234/1235) antibody was incubated with subconfluent ARCaP M cells at 4°C overnight. Either anti-goat Alexa Fluor® 546 or anti-rabbit Alexa Fluor® 488 secondary antibody (Invitrogen) was used at a dilution of 1:500. Cells were imaged on a Zeiss LSM 510 META [47] . In all cases, either a 63× or 100× Zeiss Plan-Apo oil objective was used (numerical aperture of 1.3 and 1.4, respectively). All images had contrast expansion performed in Adobe Photoshop.
Immunoprecipitation
The Immunoprecipitation Starter Pack (GE healthcare Bio-Sciences Corp., Piscataway, NJ) was used according to the manufacturer's instructions. Total lysates (1 mg) were immunoprecipitated with rabbit anti-c-MET antibody (C-12), rabbit anti-NRP1 antibody (H-286, Santa Cruz Biotechnology), or normal rabbit IgG (R&D Systems). Protein A/G Sepharose 4 Fast Flow beads were added to precipitate proteins, then washed and eluted. The samples were further processed for western blot analysis.
Apoptosis analysis
Cells were stained with an Annexin V-PE apoptosis detection kit (BD Biosciences, San Jose, CA) following the manufacturer's protocol, and measured using a fluorescence-activated cell sorting (FACS) caliber benchtop flow cytometer (Becton Dickinson, Franklin Lakes, NJ). The data were analyzed using FlowJo software (Tree Star, Inc., Ashland, OR).
Data analysis
Significance levels for comparisons of Mcl-1 expression in different Gleason score PCa were calculated by using the 2-sample t test. Treatment effects were evaluated using a two-sided Student's t test. All data represent three or more experiments. Errors are S.E. values of averaged results, and values of p < 0.05 were taken as a significant difference between means. 
